Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
Last trade$18.46
Day change-$1.03 (-5.28%)
Day range$17.94 – $19.50
Volume676,973
Market cap$1.75B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for BRVE.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BRVE, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Revenue
$0
Cost of revenue
$0
Gross profit
$0
Selling, general and administrative
$12.61M
Research and development
$17.54M
Total operating expenses
$30.15M
Operating income
-$30.15M
Interest expense
$0
Income before taxes
-$26.5M
Income taxes
$0
Net income
-$26.5M
Net income attributable to common shareholders
-$26.5M
EBITDA
-$30.15M
Basic earnings per share
-$0.51
Diluted earnings per share
-$0.51
Recent news
Company coverage with links to the original publishers.
Braveheart Bio Chairman Chris Viehbacher purchased 83,333 shares worth $1.5 million at the company's IPO price of $18 per share on August 7, 2026, expanding his direct stake by 16%. The insider purchase, combined with strong IPO demand and positive Phase 2 trial results for the company's lead cardiac myosin inhibitor candidate, signals bullishness around the clinical-stage biotech company.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.